Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cardiol Therapeutics Inc
(TSX:
CRDL
)
2.500
+0.100 (+4.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
61,620
Open
2.420
Bid (Size)
2.500 (10)
Ask (Size)
2.530 (40)
Prev. Close
2.400
Today's Range
2.340 - 2.510
52wk Range
0.7700 - 2.940
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
February 21, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Via
Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)...
Via
Newsfile
Exposures
Product Safety
Performance
YTD
+110.08%
+110.08%
1 Month
+1.21%
+1.21%
3 Month
+63.40%
+63.40%
6 Month
+127.27%
+127.27%
1 Year
+212.50%
+212.50%
More News
Read More
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
November 01, 2023
Via
Newsfile
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
October 10, 2023
Via
Benzinga
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
October 10, 2023
Via
Newsfile
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
October 10, 2023
Via
AB Newswire
Topics
Stocks
Exposures
US Equities
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
October 02, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Product Safety
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
September 19, 2023
Via
Newsfile
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Via
Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Air Pollution is a Global Heart and Lung Health Concern
July 18, 2022
Via
FinancialNewsMedia
Topics
Climate Change
Emissions
Energy
Exposures
Climate
Fossil Fuels
The Healthcare Companies Fighting the World’s Biggest Killers
July 13, 2022
Via
FinancialNewsMedia
Tackling Recurring Health Conditions Offers Hope to Patients
June 21, 2022
Via
FinancialNewsMedia
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Via
FinancialNewsMedia
Breakthroughs In Treating Killer Diseases Could Lengthen Life
June 07, 2022
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Market Movers. Today’s Top Stock Picks For New & Trending Opportunities
May 27, 2022
From
Stockhouse Publishing
Via
AccessWire
Why Orphan Drug Designation Offers Several Benefits
May 18, 2022
Via
FinancialNewsMedia
Exposures
Product Safety
Heart Failure Treatment Offers Hope to Diabetics
May 11, 2022
Via
FinancialNewsMedia
Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting
June 30, 2021
Via
Newsfile
Exposures
COVID-19
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT
June 28, 2021
Via
Newsfile
Exposures
COVID-19
Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
June 15, 2021
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
April 28, 2021
Via
Newsfile
Exposures
COVID-19
Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)
April 12, 2021
Via
Newsfile
Exposures
COVID-19
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.